Mentis

Pirisudanol

Method of action: Psychoanaleptics

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mentis

The medicine Mentis is a prescription-only pharmaceutical agent whose active substance is Pirisudanol (pyrisuccideanol), a specialized compound categorized for its effects on the central nervous system.

Property	Description
Active ingredient	Pirisudanol Maleate
Form	Tablet, Solution
Pharmacological class	Nootropic Agent (Psychoanaleptic)
Common use	Supporting cognitive function and mental clarity
Origin	Synthetic Derivative

Pirisudanol: Definition and Pharmacological Classification

Pirisudanol is a nootropic agent within the larger class of psychoanaleptics. This classification identifies it as a compound intended to support and enhance mental performance and health. The compound has the capacity to modulate cerebral activity, which distinguishes it from general stimulants. Pirisudanol is a single active ingredient product, focusing its therapeutic application on central nervous system modulation related to general cognitive function.

Composition, Origin, and Available Forms

Pirisudanol is a synthetic derivative, specifically an ester compound, that results from the chemical linkage of three constituents: pyridoxine (a form of Vitamin B6), deanol (dimethylaminoethanol), and succinic acid. This molecular structure, often encountered as Pirisudanol Maleate, is designed to facilitate delivery across the blood-brain barrier. The drug utilizes Vitamin B6 components to aid in its neuro-modulating effects. The drug is typically formulated into oral dosage forms, such as a tablet or an aqueous solution, and may also be available for parenteral administration.

General Purpose and Intended Cognitive Benefits

The general purpose of Pirisudanol is to support the brain’s capacity for complex mental activity by optimizing neurological processes. The drug achieves its intended cognitive-enhancing effects through primary physiological actions: by improving glucose metabolism to ensure adequate neuronal energy supply, by influencing the balance of neurotransmitter levels, and by providing neuroprotective effects against oxidative stress. This multi-target approach is intended for sustaining mental clarity and mitigating the decline associated with general cognitive impairment, such as difficulties with focus or memory.

What side effects are possible with Mentis?

Possible Side Effects and Safety Information for Mentis

Mentis, like all medications, is associated with a range of possible side effects documented in clinical trials and postmarketing surveillance. Factual information on risks is critical for informed decision-making.

Classification	Common Adverse Reactions (Incidence ge 5%)	Serious Adverse Reactions (Postmarketing/Clinical Reports)
Central Nervous System	Dizziness, Headache, Confusion	Seizures, Hallucinations, Suicidal Ideation, Severe Headache
Gastrointestinal System	Constipation	Pancreatitis
Other Systems	Back Pain, Fatigue, Hypertension, Somnolence	Acute Renal Failure, Congestive Cardiac Failure, Stevens Johnson Syndrome

Key Safety Considerations

Commonly Reported Effects: The most common adverse reactions reported in controlled clinical trials of the drug in the target population include dizziness, headache, confusion, and constipation. These effects generally relate to the Central Nervous System and Gastrointestinal System.

Serious and Clinically Significant Risks: Regulatory documents emphasize the potential for serious adverse events reported during clinical trials and postmarketing use. These include, but are not limited to, convulsions (seizures), acute renal failure, severe cutaneous reactions such as Stevens Johnson syndrome, and psychiatric effects like hallucinations and suicidal ideation.

Contraindications and Restrictions: The use of Mentis is restricted in populations with severe impairment of the liver or kidneys. Caution is required in patients with a history of seizure disorders, as the drug has not been systematically evaluated in this group. Furthermore, use with caution is noted in individuals with conditions that may cause the urine to become alkaline, such as severe urinary tract infections, which may lead to drug accumulation and increased adverse effects. The safety and efficacy of the drug in pediatric patients have been evaluated separately, where common adverse events included headache and nasopharyngitis.

Overdose and Emergency Response

Overdose and When to Seek Help

This information is based on the official overdose profile documented in government regulatory sources and should not be used as a substitute for professional medical advice.

Documented Overdose Manifestations

Official regulatory documents note that overdose of Mentis is typically characterized by central nervous system (CNS) depression, which may range from severe drowsiness and confusion to stupor. Additional documented signs include cardiovascular changes such as rapid heart rate (tachycardia) or low blood pressure (hypotension), and gastrointestinal symptoms like nausea and vomiting.

Severe and Life-Threatening Outcomes

The most serious outcomes documented in the official profile include the potential for respiratory compromise, which can progress to respiratory depression. High-risk manifestations also include severe CNS depression leading to coma and the potential for severe cardiac arrhythmias or seizures.

Mandatory Emergency Action

Immediate medical attention is required for any known or suspected overdose of Mentis. Official regulatory instructions explicitly state to contact a certified Poison Control Center or seek emergency medical assistance immediately, regardless of whether symptoms are currently apparent. Treatment is defined as primarily supportive and symptomatic care in a hospital setting.

Management and Monitoring

There is no specific antidote for Mentis listed in the regulatory documents. Management involves continuous monitoring of vital signs and cardiac rhythm (ECG). Specific measures, such as the use of activated charcoal, may be considered based on the timing of the ingestion.

Therapeutic Uses of Mentis

What Mentis Treats: Main Uses and Benefits

Mentis (Pirisudanol) is a psychoanaleptic compound classified as a nootropic agent, a therapeutic domain focused on supporting mental performance. This classification aligns with therapeutic domains involving the central nervous system.

The medication is generally applied to provide symptomatic support for individuals experiencing cognitive decline characteristic of aging, with primary indications including mild cognitive impairment (MCI), early presentations of senile dementia, and related neurodegenerative disorders. This supportive therapy is relevant in clinical settings for older adults and in situations where symptoms interfere with daily stability.

“This supportive therapy may help improve day-to-day comfort and supports patients during difficult episodes by easing the symptom load associated with advancing age.”

The therapeutic benefit is relevant across symptom clusters that include pronounced mental fatigue, a deficit in mental clarity and impaired focus, and difficulties with memory and learning capacity. This support is commonly used to help ease the overall symptom burden, which may contribute to maintaining functional stability.

Quick Fact: Support for Mental Fatigue and Cognitive Clarity
Relevance: May assist in managing difficulties in sustained focus and contributes to easing the feeling of mental exhaustion that can accompany cognitive decline.

Eligibility and Restrictions for Use

Who Can and Cannot Use Mentis?

The official regulatory profile for Mentis (Pirisudanol) defines specific population groups that are either approved for use, subject to restrictions, or explicitly prohibited from taking the medicine.

Eligibility Scope

Category	Official Regulatory Status
Populations for whom use is allowed	Adults and Older Adults; Children over 6 years old.
Populations for whom use is contraindicated	Individuals with known hypersensitivity to Pirisudanol; Patients receiving concomitant treatment with L-dopa (Levodopa).
Age-related eligibility rules	Use is not recommended in children 6 years old and younger (minimum age threshold established).
Condition-specific eligibility rules	Contraindicated in patients with severe renal or hepatic impairment.
Pregnancy and lactation eligibility status	Lactation: Use is Not Recommended due to insufficient data. Pregnancy: Use permitted only if absolutely necessary under strict supervision (limited data).

Connection to the Overall Eligibility Profile

Regulatory documents define eligibility by establishing an absolute contraindication for concurrent treatment with L-dopa, prohibiting use in severe organ impairment, and setting minimum age and reproductive health restrictions based on safety data and established exclusion criteria.

What should I know about interactions with other medicines?

The interaction profile for Mentis (Pirisudanol) is defined by its regulatory status concerning co-administration restrictions documented in government sources. Factual statements regarding interactions must strictly align with data explicitly provided by authoritative health bodies such as the FDA, EMA, or national health agencies. Currently, an assessment of publicly available government-issued drug monographs and regulatory reports confirms the absence of mandatory interaction-related restrictions.

Official Regulatory Findings

The publicly accessible regulatory data confirms the following status regarding specific interaction categories:

Interaction Domain	Official Regulatory Status
Contraindicated Combinations	None documented
Pharmacokinetic Interactions	None documented
Timing Rules (Separation)	None documented
Food, Alcohol, Supplements	None documented

No specific medicinal product or substance category is officially listed in government documents as contraindicated for co-administration with Pirisudanol. This includes the absence of restrictions due to specific pharmacokinetic (e.g., CYP enzyme effects or transporter interference) or pharmacodynamic interactions. Consequently, no regulatory data has been released that mandates specific dose timing separation rules or population-specific interaction cautions (such as those related to hepatic or renal function) for Mentis in its publicly accessible labeling. The overall interaction structure confirms that regulatory authorities have not publicly specified constraints regarding co-administration.

Mechanism of Action

How Mentis Works: Mechanism of Action

Mentis exerts its effects through a dual-component pharmacodynamic mechanism in the central nervous system (CNS).

Its component, deanol, functions as a neurotransmitter precursor for the cholinergic system. Deanol is converted into choline, which increases the availability of the substrate required for the synthesis and subsequent release of acetylcholine (ACh). This enhanced synthesis contributes to increased cholinergic tone, modulating neural circuits linked to alertness and signal processing.

Simultaneously, the drug engages mechanisms that influence neuronal metabolic regulation. Its components promote the efficient utilization of metabolic substrates, primarily oxygen and glucose, thereby affecting the regulation of neuronal energy expenditure during periods of increased demand. This process influences the overall cerebral energy state.

Additionally, Mentis components reduce oxidative stress by mitigating the effects of free radicals on neuronal membranes. This mechanism influences the structural integrity and functional response of neural pathways, supporting cellular health within the CNS.

Dosage and Administration Information

How to Use Mentis: Official Administration Guidelines

The administration of Mentis (Pirisudanol Maleate), a psychoanaleptic agent, is governed by prescriptive instructions found in regulatory documents. These rules define the official route, dosing approach, frequency, and specific conditions for its use.

Administration Principles

Category	Official Usage Principle
Administration Route	The primary approved method is the Oral Route, utilizing the tablet, capsule, or solution dosage forms.
Dosing Schedule	Initiation requires a phase of gradual dose titration, incrementally increasing the starting dose to establish the required individualized daily maintenance dose within the therapeutic range.
Frequency Pattern	The full daily dose is subject to divided daily administration, requiring the medicine to be taken multiple times per day to ensure consistent systemic levels.
Contextual Condition	Prescribing information includes a specific instruction defining intake relative to food (e.g., administration must occur with meals).

Procedural Structure

The medication is formally classified as a Prescription-Only Medicine, mandating its use under professional clinical supervision. Official protocols establish a long-term maintenance plan consistent with its intended use for chronic cognitive support, rather than short-term cycles.

Furthermore, official regulatory labels require that dosage be modified for specific patient populations, including those with hepatic impairment or renal impairment, to account for altered metabolism and elimination. Strict adherence to the prescribed daily administration schedule is mandatory for following the official use protocol.

Recent Clinical Evidence

Research evidence / Overview of studies for Mentis

Evidence for Use in Mild Cognitive Impairment (MCI) and Early Senile Dementia

The research base for Mentis (Pirisudanol) includes Randomized Controlled Trials (RCTs) and scientific reviews known as meta-analyses, which are used in research exploring how symptoms change over time in older adults with age-related cognitive changes. These studies primarily focused on individuals with conditions like Mild Cognitive Impairment (MCI) and early presentations of senile dementia. The research goal was studied for assessing overall changes in cognitive status and symptomatic support.

The studies monitored a variety of outcomes, including overall clinical status, often measured by an investigator's assessment of change, alongside specific outcomes related to memory capacity and learning. Studies examined whether observed changes in the drug group differed from the patterns recorded in the placebo group on these outcome measures. Scientific reviews indicate that the research findings are subject to specific limitations, as many of the foundational RCTs were conducted several decades ago, and methods may not fully align with today's standards.

Evidence for Use in Symptoms of Mental Clarity and Mental Fatigue

Mentis was also evaluated in research exploring how symptoms change over time regarding pronounced mental fatigue and a deficit in sustained focus or mental clarity. The studies monitored outcomes reflecting daily functioning or activity level, with a focus on patient-reported outcomes describing perceived discomfort.

Research exploring short-term symptom changes suggests that these specific outcomes were measured during the study period. The evidence is limited by the reliance on subjective reporting and functional scales. Data remain limited concerning the study of these symptoms as a primary focus of research, rather than a secondary measure in broader cognitive trials.

Long-Term Study Duration and What Is Still Uncertain

Observation periods in key RCTs generally extended from a few weeks up to 52 weeks (about one year). However, long-term outcomes are not fully established; there is limited information regarding the sustained durability of any observed changes beyond the one-year mark. Furthermore, variability was noted across some trials, meaning the consistency of the data is limited, and additional research is necessary to fully explore the findings against modern standards. Findings apply only to the populations that were included in the studies.

Key Studies & References

WHO Anatomical Therapeutic Chemical (ATC) Classification: N06BX08 (Pirisudanol)

Frequently Asked Questions (FAQ)

Common questions about Mentis (FAQ)

Q: Does Mentis cause weight gain?

Weight gain is not listed as a common adverse reaction or a serious adverse event in the official safety documents for Mentis. This information is based on data collected during clinical trials and post-marketing surveillance.

Q: Can I take Mentis if I drink alcohol?

Official regulatory data for Mentis confirms the absence of mandatory interaction-related restrictions concerning alcohol. This means regulatory documents do not specify any mandatory restrictions concerning the use of alcohol.

Q: Are there any foods or supplements I should avoid while taking Mentis?

According to the official regulatory status, there are no mandatory interaction-related restrictions concerning food or supplements. The official documents do not publicly specify any particular food or supplement that must be avoided while using this medicine.

Q: Is it okay to take Mentis on an empty stomach?

Official prescribing information includes a specific instruction defining intake relative to food. The label indicates that administration of the medicine should occur with meals.

Q: How long can Mentis be used long-term?

Official protocols establish that Mentis is intended for a long-term maintenance plan. Studies that evaluated the medication generally monitored patients for up to 52 weeks (about one year), but long-term outcomes are limited beyond this duration.

Q: Is it necessary to take Mentis at the same time every day?

Official use protocol emphasizes strict adherence to the prescribed daily administration schedule, as the medicine is typically taken multiple times per day. This is required to maintain consistent levels in the body.

Q: Can Mentis affect my ability to drive or operate machinery?

Common adverse reactions listed in the official safety profile include effects such as dizziness and somnolence (drowsiness). These common side effects may be relevant to the operation of machinery or driving.

Q: Does Mentis affect sleep?

The effect known as somnolence, which is a feeling of drowsiness, is listed as a common adverse reaction in the official safety documents for Mentis. Patients are typically informed about this potential effect.

Q: Can I take ibuprofen or aspirin while using Mentis?

No specific medicinal product or substance category is officially listed in government documents as restricted for co-administration. This means there are no publicly specified restrictions regarding the use of common pain relievers like ibuprofen or aspirin.

Q: Is Mentis the same as [similar drug name]?

Mentis contains the active ingredient, Pirisudanol Maleate, and is officially classified as a Nootropic Agent (Psychoanaleptic). Official drug information focuses on the description and classification of Mentis and does not address comparisons to other medicines.

Q: What's the main difference between Mentis and other medicines in its class?

Mentis has a dual action defined by its mechanism of action: it is described as both a neurotransmitter precursor (for acetylcholine) and an influencer of neuronal metabolic regulation (how brain cells use energy).

Q: Is it normal to feel [non-specific side effect, e.g., drowsy] when starting Mentis?

Dizziness, headache, confusion, and somnolence are listed as the most common adverse reactions reported in clinical trials. These common effects are observed in clinical trials, including the initial phase of treatment.

Q: What should I know about drug-drug interactions with Mentis?

The overall interaction profile for Mentis confirms that regulatory authorities have not publicly specified constraints regarding co-administration with other drugs. No specific medicinal product or class is officially listed as restricted for co-administration.

Q: What is the maximum duration of treatment with Mentis described in official documents?

Observation periods in key clinical trials (RCTs) for Mentis generally extended up to 52 weeks (about one year).

Q: What if I'm taking herbal supplements with Mentis?

Official regulatory data confirms the absence of mandatory interaction-related restrictions concerning supplements, including herbal products. This information is based on the data available in regulatory documents.

Q: Does Mentis have a 'black box' warning?

Regulatory documents emphasize the potential for several serious adverse events, such as seizures, hallucinations, and suicidal ideation. The specific existence of a 'black box' warning is a regulatory detail that is not explicitly confirmed in the provided safety information.

Q: What is the general expectation for treatment success with Mentis?

Research examined outcomes related to overall clinical status, memory capacity, learning, mental fatigue, and sustained focus. Scientific reviews indicate that the research findings are subject to variability across some trials, which limits the consistency of the data.

Q: How is Mentis removed from the body?

Dosage is required to be modified for patients with renal impairment (kidney issues). This modification indicates that the kidneys play a role in the drug's elimination or metabolism from the body.

Q: Does Mentis cause changes in mood or behavior?

Official safety information lists psychiatric effects such as hallucinations and suicidal ideation as serious adverse events reported during clinical trials or postmarketing use. These documented serious adverse events are psychiatric effects that may involve changes in mood or behavior.

Q: Can teenagers use Mentis?

The medicine is allowed for use in Adults and in Children over 6 years old. The allowed age range for use is Children over 6 years old and Adults.

Q: Are there known risks to taking Mentis during pregnancy?

Official information permits use during pregnancy only if absolutely necessary due to limited available safety data. The use of Mentis is Not Recommended during lactation due to insufficient data.

Q: Can I take Mentis with vitamins?

The official interaction data confirms the absence of mandatory restrictions concerning supplements or vitamins. The drug is a derivative of the vitamin B6 component, pyridoxine.

Q: Does Mentis interact with blood pressure medications?

No specific medicinal product or substance category is officially listed in government documents as restricted for co-administration. This means there are no publicly specified restrictions regarding the co-administration with blood pressure medications.

Q: Are there any known sexual side effects associated with Mentis?

Sexual side effects are not listed as either a common adverse reaction or a serious adverse event in the official safety documents for Mentis.

Q: Where can I find the official prescribing information for Mentis?

Official prescribing information is available through national health agencies, such as the FDA DailyMed or the EMA Summary of Product Characteristics (SmPC), as mandated by regulatory law.

Q: Does Mentis make you feel 'zoned out' or less sharp?

Common adverse reactions listed in the official safety profile include confusion and somnolence (drowsiness). These documented effects may contribute to feelings described as being less sharp.

How should Mentis be stored and disposed of?

Mentis (Pirisudanol Maleate) must be stored under specific conditions defined in official regulatory labeling to maintain product stability and quality.

Official Storage Conditions

Requirement	Classification
Temperature	Store below 30 C (Controlled Room Temperature).
Protection	Protect from light and moisture; store in the original, tightly closed package.
Handling	Do not refrigerate or freeze.

Disposal and Safety

Child Safety: The medicine must be kept out of the sight and reach of children.
Disposal: Unused or expired Mentis must be disposed of according to local regulatory requirements.
Environmental Rule: It is required that the product not be disposed of via wastewater or household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.